ClinicaliQ Trial Snapshot
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer — Recruiting • Phase I • Oncology • NCT07590934.
- What is being tested: Multiple anti-cancer agents are being evaluated for safety, tolerability, pharmacokinetics, and preliminary efficacy in a platform study design, allowing simultaneous investigation of several therapeutic approaches in metastatic prostate cancer.
- Patient eligibility overview: The study recruits participants with metastatic prostate cancer; specific eligibility criteria (performance status, prior treatment history, organ function) would be detailed in the full protocol to determine which patient subgroups can be enrolled.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Eligibility Snapshot
- :
- Participants with a diagnosis of histologically confirmed adenocarcinoma of the prostate (no small cell, neuroendocrine, sarcomatoid, spindle or signet cell). 2. Minimum life expectancy of 3 months or more. 3. Eastern Cooperative Oncology Group (ECOG) performance status of O or 1 at screening, with no deterioration. 4. PCWG3 (Prostate Cancer Working Group 3) modified RECIST Version 1.1 evaluable disease. 5. Must have received at least one novel androgen receptor pathway inhibitor (ARPI), such as enzalutamide or darolutamide or apalutamide or abiraterone acetate. 6. Must have one or more unresectable metastatic lesions. 7. Must have had prior orchiectomy and/or ongoing androgen deprivation therapy, and a castrate level of serum testosterone (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.